impact of resorce findings on hcc clinical practice
Published 7 years ago • 70 plays • Length 5:22Download video MP4
Download video MP3
Similar videos
-
2:20
dr. bruix discusses the updated findings of the resorce trial in hcc
-
5:10
understanding the resorce data in second-line hcc
-
2:31
dr. bruix on the phase iii resorce trial in hcc
-
3:48
clinical experience with regorafenib in hcc
-
4:18
the future of hcc management
-
9:15
medicare advantage risk adjustment data validation final rule fact sheet
-
21:05
what is risk adjustment
-
13:01
#hcc #triplephase #mdct #dams #medicine #unplugged
-
2:28
dr. abou-alfa discusses results of the celestial trial in advanced hcc
-
14:55
in-depth analysis of 2024 cms-hcc model v28 impact
-
1:14
dr. abou-alfa on the ongoing impact and role of regorafenib in hcc
-
1:28
dr. jordi bruix on efficacy and safety of regorafenib in hcc after sorafenib
-
2:12
the future of hcc management
-
5:53
underlying cirrhosis in the second-line setting of hcc
-
7:13
immunotherapy in hcc
-
7:46
clinical use of regorafenib in mhcc
-
7:30
progress in the management of hepatocellular carcinoma
-
5:27
second-line systemic therapy in hcc
-
45:06
how to better identify hccs in the ehr
-
2:03
dr. kaseb on research with targeted therapy in hcc
-
1:08
dr. bendell on fda approval of regorafenib in liver cancer
-
16:35
dr. finn on regorafenib for the treatment for patients with hcc